February 26, 2018 / 2:10 PM / 8 months ago

BRIEF-Adverum Biotechnologies Announces Completion Of Dosing Of First Cohort

Feb 26 (Reuters) - Adverum Biotechnologies Inc:

* ADVERUM BIOTECHNOLOGIES ANNOUNCES COMPLETION OF DOSING OF FIRST COHORT OF PATIENTS IN THE ADVANCE PHASE 1/2 CLINICAL TRIAL OF ADVM-043 GENE THERAPY FOR A1AT DEFICIENCY

* ADVANCE TRIAL CONTINUES ON TRACK, EXPECT TO REPORT PRELIMINARY DATA IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below